The Cooper Companies, Inc. with ticker code (COO) have now 14 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $130.00 and $92.12 and has a mean target at $113.15. Given that the stocks previous close was at $109.78 this indicates there is a potential upside of 3.1%. It’s also worth noting that there is a 50 day moving average of $99.93 and the 200 day MA is $95.60. The total market capitalization for the company now stands at 21.97B. Currently the stock stands at: $110.34 USD
The potential market cap would be $22,649,451,394 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 61.3, revenue per share of $19.14 and a 3.39% return on assets.
The Cooper Companies, Inc. is a global medical device company. The Company operates through two segments: CooperVision and CooperSurgical. CooperVision segment is engaged in developing, manufacturing and marketing a range of products for contact lens wearers, featuring advanced materials and optics. CooperVision segment designs its products to solve vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigue, with a broad collection of spherical, toric and multifocal contact lenses. CooperSurgical segment focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women’s health and fertility. CooperSurgical segment supplies the family health care market with a diversified portfolio of products and services. Its office and surgical offerings include products that facilitate surgical and non-surgical procedures that are commonly performed primarily by obstetricians and gynecologists.
